REBIO TECHNOLOGIES
Sustained Treatment for Chronic Eye Diseases
ReBio is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. ReBio has leveraged Sisu® to create a new franchise to transform the standard of care in the treatment of vision-threatening chronic eye diseases.
1. The Problem
25% of adults develop chronic eye disease, growing at 10% annually. Drops are unreliable for both patient and clinician, more often than not missing the target.
2. The Growing Answer
20M intravitreal injections per year globally for anti-VEGF treatments alone, some requiring monthly injections.
3. The Challenge:
Existing Sustained-Release methods have failed to deliver safe, effective, long-acting treatments.
4. The SiSu® Solution:
Depending on the indication, a single injection, or two injections per year to safely deliver sight-preserving treatment.